title: Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias.
abstract: This study assessed the cost effectiveness of inpatient antiarrhythmic therapy initiation for supraventricular tachycardias using a metaanalysis of proarrhythmic risk and a decision analysis that compared inpatient to outpatient therapy initiation. A MEDLINE search of trials of antiarrhythmic therapy for supraventricular tachycardias was performed, and episodes of cardiac arrest, sudden or unexplained death, syncope, and sustained or unstable ventricular arrhythmias were recorded. A weighted average event rate, by sample size, was calculated and applied to a clinical decision model of therapy initiation in which patients were either hospitalized for 72 hours or treated as outpatients. Fifty-seven drug trials involving 2,822 patients met study criteria. Based on a 72-hour weighted average event rate of 0.63% (95% confidence interval, 0.2% to 1.2%), inpatient therapy initiation cost $19,231 per year of life saved for a 60-year-old patient with a normal life expectancy. Hospitalization remained cost effective when event rates and life expectancies were varied to model hypothetical clinical scenarios. For example, cost-effectiveness ratios for a 40-year-old without structural heart disease and a 60-year-old with structural heart disease were $37,510 and $33,310, respectively, per year of life saved. Thus, a 72-hour hospitalization for antiarrhythmic therapy initiation is cost effective for most patients with supraventricular tachycardias.
authors.affiliation: Division of Cardiology, and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA.
authors.forename: G R
authors.initials: GR
authors.lastname: Simons
authors.forename: E L
authors.initials: EL
authors.lastname: Eisenstein
authors.forename: L J
authors.initials: LJ
authors.lastname: Shaw
authors.forename: D B
authors.initials: DB
authors.lastname: Mark
authors.forename: E L
authors.initials: EL
authors.lastname: Pritchett
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D013617:Tachycardia, Supraventricular / Q000150:complications / Q000188:drug therapy* / Q000191:economics
chemical_list: D000889:Anti-Arrhythmia Agents